logo

JAGX

Jaguar Health
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 2
Sell signal 2
stock price surged significantly
EPS Beats Expectation
RSI Overbought
Revenue Below Expectations

Key Stats

--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--

About JAGX

Jaguar Health, Inc.

A commercial stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for GI distress, including chronic, and debilitating diarrhea

Healthcare Equipment and Supplies
06/06/2013
05/13/2015
NASDAQ Stock Exchange
49
12-31
Common stock
200 Pine Street, Suite 400, San Francisco, California 94104
--
Jaguar Health, Inc., was incorporated in Delaware on June 6, 2013. The Company is a commercial-stage pharmaceutical company focused on the development of novel patented prescription medicines sustainably extracted from plants in rainforest regions for humans and animals with gastrointestinal (" GI ") diseases.

Company Financials

EPS

JAGX has released its 2024 Q4 earnings. EPS was reported at -18.50, versus the expected -18.50, meeting expectations. The chart below visualizes how JAGX has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

JAGX has released its 2024 Q4 earnings report, with revenue of 3.51M, reflecting a YoY change of 52.57%, and net profit of -10.23M, showing a YoY change of -9.94%. The Sankey diagram below clearly presents JAGX’s revenue sources and cost distribution.

Forecast

Wall Street Opinions

Price Target

Volume Profile

Trade Flow Insight

Seasonals

Community Forum

Loading...

Related News

No articles available

Related Symbols

You can ask Aime